⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARWR News
Arrowhead Research Corporation
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
businesswire.com
ARWR
Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight
globenewswire.com
CYTK
BAYRY
LLY
BCDA
MESO
TNSA
NVO
AZN
BMY
ITCI
JNJ
AMGN
ARWR
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
businesswire.com
SRPT
ARWR
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
businesswire.com
ARWR
SRPT
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO ® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
businesswire.com
ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
businesswire.com
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
businesswire.com
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
businesswire.com
ARWR
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
businesswire.com
ARWR
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
businesswire.com
ARWR